Avalun Covid-19 antigen test now on market

Categorie(s) : Events, Industry, Innovation & Society, News

Published : 1 December 2020

Startup Avalun, which calls the MINATEC High-Tech Building its home, released its Covid-19 antigen test a few days ago. This powerful growth driver will also help speed up the rollout of Avalun’s portable lab, LabPad® Evolution.

At the start of 2020, Avalun had plans to roll out its LabPad® INR in six regions across France to monitor 10,000 patients on blood thinners. But that was before Covid. The test rollout (a project called Di@pason) was postponed when participating medical biology labs were overwhelmed by the testing demands of the pandemic. Avalun rapidly switched gears, focusing its R&D on a Covid-19 antigen test and on the release of its new portable lab, the LabPad® Evolution. The company started working on the antigen test in August, and obtained CE marking in late November.

Results in 20 minutes or less

“Positive” patients with a high viral load can expect a result in just a few minutes, while a negative result can take up to 20 minutes. Compared to the conventional in-lab PCR test, Avalun’s antigen test is 92.5% effective. A nasal swab is required for the new test. Avalun’s LabPad® Evolution automatically reads the results and sends the information to secure public health data monitoring platforms.
Orders are flowing in and demand on this global market far surpasses what the company can manufacture. The LabPad® Evolution will make inroads into markets around the world—and not just in France—much faster than anticipated. Once the pandemic is behind us, Avalun will have a substantial installed base of products and will then be able to offer other kinds of tests. The company’s R&D department is already working on them!

Contact: vincent.poher@avalun.com

More information